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Abstract 
Amyloid myopathy (AM) is a rare manifesta-
tion  of  primary  systemic  amyloidosis  (AL).
Like  inflammatory  myopathies,  it  presents
with  proximal  muscle  weakness  and  an
increased creatine kinase level. We describe a
case  of  AL  with  severe,  rapidly  progressive
myopathy as the initial symptom. The clinical
manifestation and muscle biopsy were sugges-
tive of inclusion body myositis. AM was not
suspected until amyloidosis was seen in the
gastric mucosal biopsy. The muscle biopsy was
then re-examined more specifically, and Congo
red staining eventually showed vascular and
interstitial amyloid accumulation, which led to
a diagnosis of AM. The present case illustrates
the  fact  that  the  clinical  picture  of  AM  can
mimic that of inclusion body myositis. 
Introduction
Primary systemic amyloidosis (AL) is a rare
disease. Its typical presentations are nephrotic
syndrome,  cardiomyopathy,  peripheral  neu-
ropathy  and  hepatomegaly.
1,2 One  uncommon
manifestation is amyloid myopathy (AM), the
symptoms of which are usually non-specific,
typically including progressive proximal weak-
ness with an increased creatine kinase (CK)
level, macroglossia and muscle pseudohyper-
trophy.
3,4,5 Muscle weakness is atypical as the
initial symptom of the disease.
1,6 The diagnosis
of AM is usually overlooked and it is often mis-
diagnosed  as  inflammatory  myopathy,  even
when a muscle biopsy is available.
7 When sus-
pecting  AM,  Congo  red  staining  and  an
immunohistochemistry or immunofluoresence
assay should be performed. Furthermore, the
use of MRI for evaluating neuromuscular dis-
orders  and  inflammatory  myopathies  has
become  increasingly  common,  especially  in
cases of polymyositis.
8,9 We present here a case
of  AL  with  severe  and  rapidly  progressive
myopathy as the initial symptom. 
Clinical summary
The patient was a 65-year-old man with a
history  of  hypertension  and  obesity  (weight
144 kg) who presented with proximal muscle
weakness in the legs and a 35 kg weight loss.
No familial occurrence of muscle diseases was
reported. At the first clinical examination after
two years of experiencing fatigue, the patient
showed slight proximal muscle weakness cor-
responding  to  4/5  on  the  Medical  Research
Council (MRC) scale and minor weakening of
the tendon reflexes but was able to walk with-
out  support.  Muscle  weakness  progressed
within  six  months,  however,  forcing  the
patient to use a walking aid. He then had grade
3 symptoms on the MRC scale in the shoulder
girdle and bilaterally in the thigh muscles, with
grade  4  in  the  distal  hand  and  leg  muscle
groups. In addition, the new findings included
mild dysphagia, macroglossia and an absence
of  tendon  reflexes.  No  muscle  atrophy  was
established and sensory functions were intact.
The results of brain MRI and a cerebrospinal
fluid analysis were normal. 
Laboratory findings included elevated serum
creatine kinase (CK) and serum aldolase lev-
els (Table 1). Liver function tests were abnor-
mal,  but  MCV  was  slightly  elevated.  Serum
transferrine,  protein  electrophoresis  and
immunofixation findings were normal, whilst
serum ferritine was elevated. The plasma albu-
min level was low, and marked proteinuria was
observed.  An  electromyography  (EMG)
revealed proximal fibrillation and motor unit
potentials of short duration, low amplitude and
a polyphasic character and insertional activity.
The myopathy specific EMG findings aroused
suspicions  of  inclusion  body  myositis  and
polymyositis.  The  patient  had  arrhythmic
episodes  of  supraventricular  tachycardia
(SVT), and a chest X-ray film showed cardiac
dilatation. Echocardiography revealed marked
left ventricular hypertrophy. The ejection frac-
tion was 55%, and the myocardium was slight-
ly abnormal, indicating muscle disease. 
Muscle magnetic resonance imaging (MRI)
was  performed  with  T1,  short  tau  inversion
recovery (STIR) and T2 FAT SAT axial projec-
tions (Figure 1). Axial T2 fat suppression mag-
netic resonance imaging of the thighs showed
a mildly increased signal intensity in the pos-
terior muscles, while coronal T2 fat suppres-
sion magnetic imaging showed a coarse retic-
ular  pattern  in  the  subcutaneous  fat  of  the
lower extremities. A left vastus lateralis mus-
cle  biopsy  showed  mainly  non-specific
changes, but there was some evidence sugges-
tive of inclusion body myositis. An abdominal
ultrasonography  showed  the  presence  of  a
slightly clear liver. The abdominal CT results
were normal. The provisional diagnosis at this
stage  was  considered  to  be  inclusion  body
myositis.  A  gastroscopy  was  performed  on
account of elevated liver enzymes and a suspi-
cion of celiac disease, and biopsies from the
duodenum,  antrum  and  corpus  revealed  dif-
fuse mucosal, submucosal and vascular amy-
loid  accumulation.  The  histological  findings
conformed  to  primary  amyloidosis.  Immuno-
fixation of serum and urine also revealed a
minimal amount of lambda light chains. The
amount of plasma cells in a bone marrow biop-
sy was normal. In view of the gastric biopsy
findings and the diagnosis of primary amyloi-
dosis,  the  muscle  biopsy  was  re-examined
more specifically. Congo red staining eventual-
ly showed vascular and extracellular amyloid
accumulation, which led to a diagnosis of AM.
Despite  the  gastrointestinal  changes,  the
patient did not have any clinical symptoms of
this.
After  the  IBM  diagnosis,  the  patient  was
treated  with  prednisone  100  mg/day  for  two
months and then at a decreasing dosage for
three months. Since the muscle weakness had
markedly  progressed  in  spite  of  this  pred-
nisone medication, the treatment was stopped
after five months. Immunoglobulin 0.4 mg/kg
i.v. was given for five days, leading to a minor
improvement in muscle strength, so that the
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oral melphalan and prednisone treatment was
also  started  after  the  diagnosis  of  amyloid
myopathy, the total target dose of melphalan
being 740 mg, while prednisone was given 100
mg p.o. once a day for four days. Only a minor
response to the medication was seen as far as
the progression of muscle weakness and other
symptoms  during  one  year  of  follow-up  was
concerned. The patient died of pneumonia at
the age of 69 years. No autopsy was performed.
Pathological findings
The first examination of the left vastus lat-
eralis  muscle  biopsy  showed  changes  sug-
gesting neurogenic atrophy, regeneration and
some  rimmed  vacuoles.  NADH-Tr  and
trichrome staining results were normal, but
SDH-COX staining revealed some COX-nega-
tive fibers. No MCH-class I upregulation was
seen on the muscle membranes nor any fiber
necrosis. Although the muscle biopsy findings
were mainly non-specific, there was some evi-
dence suggestive of inclusion body myositis. 
A  gastroscopy  was  performed  later  on
account of elevated liver enzymes and a suspi-
cion of celiac disease, and duodenum, antrum
and corpus biopsies revealed diffuse mucosal,
submucosal and vascular amyloid accumula-
tion  which  was  resistant  to  potassium  per-
manganate digestion. An immunohistochemi-
cal assay was negative for amyloid A, but the
accumulation  was  positive  for  lambda  light
chain staining. The histological findings con-
formed to primary amyloidosis. The number
of plasma cells in a bone marrow biopsy was
normal. In view of the gastric biopsy findings
and the diagnosis of primary amyloidosis, the
muscle  biopsy  was  examined  again  more
specifically.  Congo  red  staining  eventually
showed  vascular  and  extracellular  amyloid
accumulation, which led to a diagnosis of AM
(Figure  2).  An  immunohistochemical  assay
for amyloid A was negative, and kappa and
lambda light chain stainings were inconclu-
sive.
Discussion 
The first recognised patient presenting with
amyloid  involvement  in  muscle,  the  condition
known  as  AM,  was  reported  by  Lubarsch  in
1929,
10 and it has now been reported in three of
the largest series that myopathy is rarely caused
by amyloidosis.
1,4,6,7The symptoms of AM are usu-
ally non-specific, including progressive proximal
weakness with an elevated creatine kinase level,
macroglossia and muscle pseudohypertrophy as
the typical features.
3,4,5 We described a case of AL
with severe, rapidly progressive myopathy as the
initial symptom. The patient had suffered from
mild muscle weakness for 2.5 years, followed by a
rapid progression of the condition and the onset
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Table 1. Abnormal laboratory test findings.
Laboratory test Laboratory values Reference values 
S-CK (U/L) 1900-2200  40-280 (for men)
S-aldolase (U/L) 18  <5 
E-MCV (fL) 100-106  82-98 
P-albumin (g/L) 24-35  36-45 
U-protein (mg/L) 2100  <200 
S- ferritine (ug/L) 797  20-250 
P-ALAT (U/L) 90-196  10-70
P-GT (U/L) 242-1284 15-115
Figure 1. (a) Axial T2 fat suppression mag-
netic  resonance  imaging  of  the  patient’s
thighs. Mildly increased signal intensity is
visible in the posterior muscles. (b) Coronal
T2 fat suppression magnetic imaging show
a  coarse  reticular  pattern  in  the  subcuta-
neous fat of the lower extremities.
Figure 2. (a) Biopsy of the vastus lateralis muscle shows the vascular wall and an intersti-
tial accumulation of amyloid (Congo red), (b) expression of neonatal myosin in atroph-
ic cells (myosin heavy chain neonatal immunoperoxidase staining, original magnification
x 20), (c) a COX-negative fiber (succinate dehydrogenase – cytochrome oxidase double
staining) and (d) a duodenal mucosal biopsy containing amyloid (Congo red). Scale bar
100 µm (figure a-c), 200 µm (figure d).of other clinical symptoms such as dysphagia and
macroglossia.  Visceral  manifestations  of  AL,
including cardiomyopathy, nephropathy and gi-
changes, were also observed. Weakness of knee
extensors with absent knee reflexes was promi-
nent in the early course of the disease suggest-
ing the diagnosis of IBM although distal involve-
ment in the hands was observed later.
Although  amyloid  myopathy  is  a  well-
described disorder, it is often overlooked, for two
reasons: first, it is rarely observed clinically, and
second, a broad span of differential diagnoses is
needed. It is usually misdiagnosed as inflamma-
tory myopathy, even given a muscle biopsy, as
seen here and reported by others. Three cases of
AM mimicking polymyositis have been reported
lately, all showing similarities in clinical, neuro-
physiological and muscle biopsy findings when
stained only with hematoxylin-eosin. In all three
cases, the original muscle biopsy samples were
analyzed retrospectively with Congo red staining,
which  led  to  a  proper  diagnosis  of  AM.
6,11,12
Furthermore, Spuler et al. found that the routine
use of Congo red-stained sections increased the
frequency of a diagnosis of AM 10-fold. The pres-
ent case illustrates the difficulty of differentiat-
ing AM from inflammatory myopathies: the first
suspected diagnosis was inclusion body myositis.
The presence of neonatal myosin in some fibers
reflects the immaturity/regenerative activity of
the muscle and is a sign of a pathological state in
the muscle. COX-negative fibers are a common
finding in IBM, but  non-specific, as they are
often seen in the muscle of aged people. AM was
not suspected until amyloidosis was seen in the
gastric mucosal biopsy. Congo red staining even-
tually showed vascular and extracellular amyloid
accumulations in the original muscle biopsy sec-
tions, which led to a diagnosis of AM. The use of
MRI  for  the  evaluation  of  inflammatory
myopathies  and  neuromuscular  disorders  has
become  increasingly  common,  especially  in
cases  of  polymyositis,
8,9 and  its  usefulness  for
diagnosing AM has also been described.
11 Hull et
al. reported a case of a patient with the occur-
rence of abnormal subcutaneous fat in MRI and
increased T2 signal intensity and minimal signal
intensity alternation in the muscles, and estab-
lished that these findings coupled with minimal
muscular  involvement  constituted  a  unique
guide to a proper diagnosis of primary AM. This
is consistent with the previous MRI findings in 2
patients described by Metzler et al.In particular a
hypointense reticular appearance for the subcu-
taneous fat in MRI distinguishes AM from many
other  neuromuscular  conditions.
12,13 Further-
more, in the case of the patient described by Hull
et al., MRI also revealed decreased T1 signaling
in  the  bone  marrow,  suggesting  hematologic
malignancies. In the present case the muscle
MRI revealed evidence suggestive of atrophy and
oedema in the muscles of the hips, thighs and
calves.  Nevertheless,  as  noticed  after  the
patient’s  death,  the  MRI  had  been  performed
without using a muscle-specific protocol, so that
the finding remained inconclusive. In summary,
we have reported here on a well-described case of
the  rarely  occurring  disease  AM.  This  case
demonstrates that AM can masquerade as IBM,
which is known to be a more common disorder.
The inflammatory myopathies are increasingly
being evaluated using MRI, which can be of prac-
tical  significance  in  differentiating  AM  from
other muscle diseases, targeting affected mus-
cles for biopsy and assessing disease activity.
12In
addition, MRI is of use when performed with an
appropriate  muscle-specific  protocol.  To  clarify
the etiological diagnosis of myopathy, however,
Congo red staining and immunohistochemical
testing should be performed.
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